Quality of Life in Greek Hemodialysis Patients Receiving Zemplar Intravenous

1. Patients with chronic kidney disease stage 5 undergoing hemodialysis and receiving paricalcitol iv for more than 1 month. 2. Patients with a RAND 36-Item Health Survey completed 10 to 35 days before paricalcitol iv initiation 3. Patients with baseline parathormone ≥ 300 pg/mL 4. Patients willing to give their informed consent to participate in the study. 5. Patients should not receive vitamin D-related compounds or cinacalcet for 3 months prior to entering the study 6. Patients must be on steady regimen for anemia, hypertension and diabetes for the past 30 days

1. Patients with a history of clinically significant intolerance or sensitivity to vitamin D or any ingredients of the product. 2. Patients with persistent hypercalcemia or evidence of vitamin D toxicity. 3. Patients with a continuous increase in serum (calcium x phosphorus) product greater than 65. 4. Pregnant or lactating female patients. 5. Patients who have previously undergone parathyroidectomy